CA2189983A1 - Modulateur de recepteurs de la super-famille tnf/ngf et recepteurs oligomeres solubles de la super-famille tnf/ngf - Google Patents

Modulateur de recepteurs de la super-famille tnf/ngf et recepteurs oligomeres solubles de la super-famille tnf/ngf

Info

Publication number
CA2189983A1
CA2189983A1 CA002189983A CA2189983A CA2189983A1 CA 2189983 A1 CA2189983 A1 CA 2189983A1 CA 002189983 A CA002189983 A CA 002189983A CA 2189983 A CA2189983 A CA 2189983A CA 2189983 A1 CA2189983 A1 CA 2189983A1
Authority
CA
Canada
Prior art keywords
fas
tnf
cells
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002189983A
Other languages
English (en)
Inventor
David Wallach
Mark Boldin
Igor Mett
Eugene Varfolomeev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL109632A external-priority patent/IL109632A/en
Application filed by Individual filed Critical Individual
Priority to CA002490080A priority Critical patent/CA2490080A1/fr
Publication of CA2189983A1 publication Critical patent/CA2189983A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nouvelles protéines qui se lient aux domaines intracellulaires des TNF-Rs (récepteurs de la famille du facteur de nécrose tumorale) p55 et p75 et de Fas-R, capables de moduler la fonction des TNF-Rs p55 et p75 et de Fas-R, et séquences d'ADN les codant. La présente invention concerne également de nouveaux TNF-Rs oligomères solubles, des Fas-R oligomères et des récepteurs oligomères présentant un mélange de TNF-Rs et de Fas-Rs. La présente invention concerne en outre des procédés de préparation et d'utilisation de toutes les substances susmentionnées.
CA002189983A 1994-05-11 1995-05-11 Modulateur de recepteurs de la super-famille tnf/ngf et recepteurs oligomeres solubles de la super-famille tnf/ngf Abandoned CA2189983A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002490080A CA2490080A1 (fr) 1994-05-11 1995-05-11 Modulateur de recepteurs de la super-famille tnf/ngf et recepteurs oligomeres solubles de la super-famille tnf/ngf

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL109632A IL109632A (en) 1994-05-11 1994-05-11 Modulators of the function of tnf receptors
IL109632 1994-05-11
IL11112594A IL111125A0 (en) 1994-05-11 1994-10-02 Soluble oligomeric tnf/ngf super family ligand receptors and their use
IL111125 1994-10-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002490080A Division CA2490080A1 (fr) 1994-05-11 1995-05-11 Modulateur de recepteurs de la super-famille tnf/ngf et recepteurs oligomeres solubles de la super-famille tnf/ngf

Publications (1)

Publication Number Publication Date
CA2189983A1 true CA2189983A1 (fr) 1995-11-23

Family

ID=26322830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002189983A Abandoned CA2189983A1 (fr) 1994-05-11 1995-05-11 Modulateur de recepteurs de la super-famille tnf/ngf et recepteurs oligomeres solubles de la super-famille tnf/ngf

Country Status (10)

Country Link
EP (1) EP0759984A4 (fr)
JP (1) JP3966387B2 (fr)
KR (1) KR100404737B1 (fr)
CN (2) CN1329512C (fr)
AU (1) AU703919B2 (fr)
CA (1) CA2189983A1 (fr)
FI (1) FI964509L (fr)
IL (1) IL111125A0 (fr)
NO (1) NO321514B1 (fr)
WO (1) WO1995031544A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663070A (en) * 1993-11-15 1997-09-02 Lxr Biotechnology Inc. Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
US5712381A (en) * 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US5849501A (en) * 1994-10-19 1998-12-15 Genetics Institute, Inc. TNF receptor death domain ligand proteins and method to identify inhibitors of ligand binding
US5852173A (en) * 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
US5847099A (en) * 1994-10-19 1998-12-08 Genetics Institute, Inc. TNF receptor death domain ligand proteins
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US7097972B1 (en) 1995-02-13 2006-08-29 Regents Of The University Of Michigan Method and composition for regulating apoptosis
US6015665A (en) * 1995-02-13 2000-01-18 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US6060238A (en) * 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
WO1996025941A1 (fr) * 1995-02-22 1996-08-29 Yeda Research And Development Co. Ltd. Modulateurs de proteines regulatoires
US6355780B1 (en) 1995-02-22 2002-03-12 Yeda Research And Development Co. Ltd. Antibodies to the death domain motifs of regulatory proteins
US6747138B1 (en) 1995-04-03 2004-06-08 Regents Of The University Of Michigan Methods and compositions for regulating Fas-associated apoptosis
US7807783B1 (en) 1995-04-03 2010-10-05 The Regents Of The University Of Michigan Methods and compositions for regulating FAS-associated apoptosis
US6399327B1 (en) 1995-07-16 2002-06-04 Yeda Research And Development Co. Ltd. Modulators of the function of FAS receptors and other proteins
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
SI0894141T1 (en) 1996-02-20 2005-10-31 Applied Research Systems Ars Holding N.V. Hybrid proteins which form heterodimers
BR9707589A (pt) 1996-02-20 2000-01-04 Applied Research Systems Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular.
CA2249206A1 (fr) 1996-04-01 1997-10-09 Genentech, Inc. Polypeptides de l'apoptose apo-2l1 et apo-3
WO1998006839A1 (fr) * 1996-07-15 1998-02-19 Human Genome Sciences, Inc. Proteine de type cd44
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
CA2273185A1 (fr) 1996-11-05 1998-05-14 Board Of Regents, The University Of Texas System Compositions et utilisations relatives a la sentrine, une proteine de protection contre la mort cellulaire
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
JP2001508648A (ja) 1996-11-06 2001-07-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍壊死因子レセプター放出酵素、酵素を含む組成物、およびその使用方法
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US7001992B2 (en) 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
ATE487737T1 (de) * 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
IL121746A0 (en) * 1997-06-05 1998-02-22 Yeda Res & Dev Modulators of intracellular cell death and cell survival pathways
US6051385A (en) * 1997-10-22 2000-04-18 The Regents Of The University Of Michigan Compositions and methods for identifying and testing therapeutics against HSV infection
WO1999028465A2 (fr) * 1997-11-28 1999-06-10 The Regents Of The University Of California Molecules pias reconnaissant et fixant les proteines stat et procedes d'utilisation
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
US6207422B1 (en) * 1998-04-17 2001-03-27 The Metrohealth System Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same
EP1022027A1 (fr) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonistes du TNF (Tumor necrosis factor) et leurs utilisations contre l'endometriose
JP2001078776A (ja) 1999-09-14 2001-03-27 Inst Of Physical & Chemical Res Ｎａｄｅ結合蛋白質
ES2706403T3 (es) 2008-12-10 2019-03-28 Joslin Diabetes Center Inc Métodos para diagnosticar y predecir una enfermedad renal
WO2014127835A1 (fr) 2013-02-22 2014-08-28 Christian-Albrechts-Universität Zu Kiel Gène de résistance dérivé d'une plante

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0939121B2 (fr) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. Protéines liant le TNF
CA2067031C (fr) * 1991-04-26 2003-02-18 Shigekazu Nagata Adn codant pour l'antigene de surface de cellules humaines

Also Published As

Publication number Publication date
AU2546995A (en) 1995-12-05
EP0759984A4 (fr) 2002-06-26
CN1173033C (zh) 2004-10-27
WO1995031544A1 (fr) 1995-11-23
CN1616661A (zh) 2005-05-18
NO321514B1 (no) 2006-05-15
FI964509A0 (fi) 1996-11-08
CN1329512C (zh) 2007-08-01
AU703919B2 (en) 1999-04-01
FI964509L (fi) 1997-01-09
FI964509A7 (fi) 1997-01-08
CN1152937A (zh) 1997-06-25
EP0759984A1 (fr) 1997-03-05
JPH10500568A (ja) 1998-01-20
NO964741D0 (no) 1996-11-08
JP3966387B2 (ja) 2007-08-29
KR100404737B1 (ko) 2004-05-03
NO964741L (no) 1997-01-09
IL111125A0 (en) 1994-12-29
KR970703419A (ko) 1997-07-03

Similar Documents

Publication Publication Date Title
CA2189983A1 (fr) Modulateur de recepteurs de la super-famille tnf/ngf et recepteurs oligomeres solubles de la super-famille tnf/ngf
Vandenabeele et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma.
US7728111B2 (en) Anti-p55 TNF receptor antibody
Gruss et al. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas
Pennica et al. Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation.
US6579697B1 (en) Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
KR20040019105A (ko) ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
EA015620B1 (ru) УЛУЧШЕННЫЕ ДИМЕРЫ sgp130FC
Crowe et al. Specific induction of 80-kDa tumor necrosis factor receptor shedding in T lymphocytes involves the cytoplasmic domain and phosphorylation.
CA2207815C (fr) Modulateurs de la fonction des recepteurs de fas/ap01
EP0813419B1 (fr) Modulateurs de proteines regulatoires
US7101675B2 (en) Modulators of regulatory proteins
RU2273664C2 (ru) ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ СПОСОБНОСТЬЮ СВЯЗЫВАТЬСЯ С ВНУТРИКЛЕТОЧНЫМ ДОМЕНОМ p-55 TNF-РЕЦЕПТОРА, МОЛЕКУЛА ДНК, КОДИРУЮЩАЯ ЭТОТ ПОЛИПЕПТИД, ВЕКТОР ЭКСПРЕССИИ И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА
US7083788B2 (en) Modulators of the function of receptors of the TNF/NGF receptor family and other proteins
Lorz et al. Trail and kidney disease
US7323548B2 (en) Modulators of the function of FAS/APO1 receptors
AU747029B2 (en) Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
AU714907B2 (en) Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
Ohara et al. Effect of gene transfer of tumor necrosis factor receptors into human lung carcinoma cell line
Ryffel et al. Correction of the TNF‐LTα‐Deficient Phenotype by Bone Marrow Transplantation
US7108999B1 (en) Modulators of the function of FAS/AP01 receptors
CA2490080A1 (fr) Modulateur de recepteurs de la super-famille tnf/ngf et recepteurs oligomeres solubles de la super-famille tnf/ngf
McKall-Faienza The role of TNFRp55 in autoimmunity
PennicaS et al. Biochemical Properties of the 75-kDa Tumor Necrosis Factor Receptor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued